Ocular Therapeutix posts SOL-1 win
What happened
- Ocular Therapeutix said on February 17 that SOL-1, its phase 3 wet AMD trial, beat aflibercept 2 mg on the primary endpoint at week 36. - The headline number was 74.1% versus 55.8% for vision maintenance, with a 17.5-point risk difference and p=0.0006 after equal loading. - It matters because SOL-1 targets a superiority label in wet AMD, while SOL-R could turn durability into a filing package.
Why it matters
Retina drugs are a durability business now. The basic problem in wet age-related macular degeneration is not that doctors lack medicines that work — it’s that the medicines usually wear off fast enough to keep patients coming back for repeated eye injections. Ocular Therapeutix says its phase 3 SOL-1 trial just cleared a big hurdle by showing AXPAXLI beat standard aflibercept 2 mg on a superiority endpoint, not just a non-inferiority one. That is a more ambitious claim, and it lands in a market where “works about as well” is no longer enough. (ophthalmologytimes.com) ### What is AXPAXLI, exactly? AXPAXLI — also called OTX-TKI in the trial record — is an investigational intravitreal hydrogel that carries axitinib, a tyrosine kinase inhibitor aimed at VEGF-driven disease in the retina. The pitch is simple: put a longer-acting drug depot inside the e(ophthalmologytimes.com)cifically in treatment-naïve wet AMD. (clinicaltrials.gov) ### What did SOL-1 actually test? SOL-1 enrolled 344 evaluable, treatment-naïve wet AMD patients across more than 100 sites in the U.S. and Argentina. The design matters: everyone first got two aflibercept 2 mg loading injections, and only patients who hit a strong early response were randomized 1:1 to a single dose of AXPAXLI 0.45 mg or a single(clinicaltrials.gov) comparison — it was a head-to-head after the same setup. (ophthalmologytimes.com) ### Why is “superiority” a big deal? Because retina trials often aim for non-inferiority — basically, prove the new thing is not meaningfully worse while maybe offering convenience. SOL-1 was built to do more than that. The primary endpoint was the share of patients who maintained vis(ophthalmologytimes.com)riority label under FDA draft guidance for wet AMD therapies. (ophthalmologytimes.com) ### So what were the numbers? The topline readout was strong. At week 36, 74.1% of patients on AXPAXLI maintained vision versus 55.8% on aflibercept 2 mg, for a 17.5 percentage-point risk difference with p=0.0006. Ocular also said AXPAXLI showed either statistical significance or nume(ophthalmologytimes.com)ed results, not a full paper or conference dataset yet. (ophthalmologytimes.com) ### Did the effect hold up past week 36? Early signs say yes. In later discussion of the readout, investigators highlighted durability through week 52, with 65.9% of AXPAXLI patients maintaining vision versus 44.2% on aflibercept. They also pointed to better central subfield thickness(ophthalmologytimes.com) fewer extra injections, more staying power. (ophthalmologytimes.com) ### Why did Ocular choose this odd trial setup? Because the company is trying to prove durability cleanly. By giving both arms the same aflibercept loading phase first, SOL-1 asks a sharper question: once patients are stabilized, which single treatment keeps them (ophthalmologytimes.com)retina specialists actually think about maintenance. (ophthalmologytimes.com) ### What happens next? SOL-1 is only half the package. Ocular has said SOL-R — a separate phase 3 trial that compares AXPAXLI every 6 months against on-label aflibercept every 8 weeks, plus an aflibercept 8 mg masking arm — is meant to help support an NDA after positive SOL-1 and SOL-R results. SOL-R had reached its 555-patient randomization target by November 2025. (ophthalmologytimes.com) ### Bottom line This looks like a real win, not a cosmetic one. But the full value of the win depends on the missing pieces — complete safety data, full secondary endpoints, and whether SOL-R turns one strong readout into a filing-ready story. (ophthalmologytimes.com)
Key numbers
- Ocular Therapeutix said on February 17 that SOL-1, its phase 3 wet AMD trial, beat aflibercept 2 mg on the primary endpoint at week 36.
- The headline number was 74.1% versus 55.8% for vision maintenance, with a 17.5-point risk difference and p=0.0006 after equal loading.
- It matters because SOL-1 targets a superiority label in wet AMD, while SOL-R could turn durability into a filing package.
- Ocular Therapeutix says its phase 3 SOL-1 trial just cleared a big hurdle by showing AXPAXLI beat standard aflibercept 2 mg on a superiority endpoint, not just a non-inferiority one.
What happens next
- Because retina trials often aim for non-inferiority — basically, prove the new thing is not meaningfully worse while maybe offering convenience.
- (ophthalmologytimes.com) What happens next?
- SOL-R had reached its 555-patient randomization target by November 2025.
Quick answers
What happened in Ocular Therapeutix posts SOL-1 win?
Ocular Therapeutix said on February 17 that SOL-1, its phase 3 wet AMD trial, beat aflibercept 2 mg on the primary endpoint at week 36. The headline number was 74.1% versus 55.8% for vision maintenance, with a 17.5-point risk difference and p=0.0006 after equal loading. It matters because SOL-1 targets a superiority label in wet AMD, while SOL-R could turn durability into a filing package.
Why does Ocular Therapeutix posts SOL-1 win matter?
Retina drugs are a durability business now. The basic problem in wet age-related macular degeneration is not that doctors lack medicines that work — it’s that the medicines usually wear off fast enough to keep patients coming back for repeated eye injections. Ocular Therapeutix says its phase 3 SOL-1 trial just cleared a big hurdle by showing AXPAXLI beat standard aflibercept 2 mg on a superiority endpoint, not just a non-inferiority one. That is a more ambitious claim, and it lands in a market where “works about as well” is no longer enough. (ophthalmologytimes.com) What is AXPAXLI, exactly? AXPAXLI — also called OTX-TKI in the trial record — is an investigational intravitreal hydrogel that carries axitinib, a tyrosine kinase inhibitor aimed at VEGF-driven disease in the retina. The pitch is simple: put a longer-acting drug depot inside the e(ophthalmologytimes.com)cifically in treatment-naïve wet AMD. (clinicaltrials.gov) What did SOL-1 actually test? SOL-1 enrolled 344 evaluable, treatment-naïve wet AMD patients across more than 100 sites in the U.S. and Argentina. The design matters: everyone first got two aflibercept 2 mg loading injections, and only patients who hit a strong early response were randomized 1:1 to a single dose of AXPAXLI 0.45 mg or a single(clinicaltrials.gov) comparison — it was a head-to-head after the same setup. (ophthalmologytimes.com) Why is “superiority” a big deal? Because retina trials often aim for non-inferiority — basically, prove the new thing is not meaningfully worse while maybe offering convenience. SOL-1 was built to do more than that. The primary endpoint was the share of patients who maintained vis(ophthalmologytimes.com)riority label under FDA draft guidance for wet AMD therapies. (ophthalmologytimes.com) So what were the numbers? The topline readout was strong. At week 36, 74.1% of patients on AXPAXLI maintained vision versus 55.8% on aflibercept 2 mg, for a 17.5 percentage-point risk difference with p=0.0006. Ocular also said AXPAXLI showed either statistical significance or nume(ophthalmologytimes.com)ed results, not a full paper or conference dataset yet. (ophthalmologytimes.com) Did the effect hold up past week 36? Early signs say yes. In later discussion of the readout, investigators highlighted durability through week 52, with 65.9% of AXPAXLI patients maintaining vision versus 44.2% on aflibercept. They also pointed to better central subfield thickness(ophthalmologytimes.com) fewer extra injections, more staying power. (ophthalmologytimes.com) Why did Ocular choose this odd trial setup? Because the company is trying to prove durability cleanly. By giving both arms the same aflibercept loading phase first, SOL-1 asks a sharper question: once patients are stabilized, which single treatment keeps them (ophthalmologytimes.com)retina specialists actually think about maintenance. (ophthalmologytimes.com) What happens next? SOL-1 is only half the package. Ocular has said SOL-R — a separate phase 3 trial that compares AXPAXLI every 6 months against on-label aflibercept every 8 weeks, plus an aflibercept 8 mg masking arm — is meant to help support an NDA after positive SOL-1 and SOL-R results. SOL-R had reached its 555-patient randomization target by November 2025. (ophthalmologytimes.com) Bottom line This looks like a real win, not a cosmetic one. But the full value of the win depends on the missing pieces — complete safety data, full secondary endpoints, and whether SOL-R turns one strong readout into a filing-ready story. (ophthalmologytimes.com)
